Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 94% above its 1-year average of 51.56%, near the high end of its 1-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+141.66%
vs the sector median at left
Generate Biomedicines, Inc.
Market Cap
$1.80B
Gross Margin
100.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.79B
Gross Margin
-319.36%
TTM Avg
-798.46%
3Y Avg
-813.46%
5Y Avg
-704.28%
Market Cap
$1.81B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.77B
Gross Margin
21.37%
TTM Avg
23.53%
3Y Avg
23.33%
5Y Avg
22.63%
Market Cap
$1.82B
Gross Margin
58.56%
TTM Avg
71.56%
3Y Avg
79.01%
5Y Avg
81.74%
Market Cap
$1.85B
Gross Margin
9.22%
TTM Avg
11.32%
3Y Avg
13.89%
5Y Avg
14.07%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.80B | 100.00% | N/A | N/A | N/A |
| Xencor, Inc. (XNCR)vs › | $1.79B | 91.63% | -7.22% | 16.08% | 9.32% |
| Absci Corporation (ABSI)vs › | $1.79B | -319.36% | -798.46% | -813.46% | -704.28% |
| Novavax, Inc. (NVAX)vs › | $1.82B | 93.67% | 81.97% | 61.43% | 74.28% |
| Novocure Ltd (NVCR)vs › | $1.77B | 76.13% | 75.94% | 76.33% | 77.05% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 72.90% | 70.08% | 67.68% | 66.96% |
| Surgery Partners, Inc. (SGRY)vs › | $1.77B | 21.37% | 23.53% | 23.33% | 22.63% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | 58.56% | 71.56% | 79.01% | 81.74% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 9.22% | 11.32% | 13.89% | 14.07% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | 83.34% | 81.78% | 81.39% | 75.51% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 54.69% |
| 2025-12-31 | 0.00% |
